XtalPi-Enabled PRMT5 Inhibitor PEP08 Reaches Phase I Enrollment Milestone in Solid Tumor Trial
核心洞察
PEP08 (搜索), a next-generation PRMT5 inhibitor discovered through XtalPi (搜索)'s AI and robotics platform, has successfully begun patient enrollment in a Phase I solid tumor trial in Australia and Taiwan.
The drug targets MTAP (搜索)-deleted tumors found in 10-15% of all human cancers and was designed to overcome dose-limiting hematological toxicities seen with first-generation PRMT5 inhibitors.
Preclinical data presented at 2025 AACR demonstrated PEP08 (搜索)'s superior efficacy compared to other clinical-stage MTA-cooperative PRMT5 inhibitors across multiple tumor models.
XtalPi (搜索) (2228.HK) and PharmaEngine (搜索) (4162.TWO) announced that PEP08 (搜索), a next-generation PRMT5 inhibitor discovered via XtalPi's AI and robotics platform, has successfully begun patient enrollment in a Phase I solid tumor trial. The enrollment milestone represents a significant advancement for the synthetic lethality program, which received clinical clearance in June 2025 and is currently being evaluated in Australia and the Taiwan region.
Novel Mechanism Targets MTAP-Deleted Tumors
PEP08 (搜索) was designed using XtalPi (搜索)'s integrated quantum physics, AI, and robotics-powered platform to overcome the dose-limiting hematological toxicities associated with first-generation PRMT5 inhibitors. The molecule exploits an innovative MTA-cooperative binding mode to specifically target MTAP (搜索)-deleted tumors, a genomic alteration found in 10-15% of all human cancers. Higher frequencies of this alteration are observed in non-small cell lung cancer (NSCLC (搜索)), pancreatic cancer (搜索), and glioblastoma (搜索).
Preclinical data presented at the 2025 American Association for Cancer Research (AACR) meeting demonstrated PEP08 (搜索)'s superior efficacy compared to other clinical-stage MTA-cooperative PRMT5 inhibitors across multiple MTAP (搜索)-deleted tumor models, supporting a potential best-in-class profile.
Expanding Partnership in Synthetic Lethality
Building on PEP08 (搜索)'s success at the drug discovery stage, XtalPi (搜索) and PharmaEngine (搜索) have initiated a second project targeting a different undisclosed synthetic lethality mechanism. The collaboration combines PharmaEngine's oncology expertise with XtalPi's AI and robotics molecular design capabilities to capture additional market share in the synthetic lethality space.
The synthetic lethality market represents a significant commercial opportunity, with global market projections showing growth from $4.2 billion to $17.6 billion by 2033, representing a 17.3% compound annual growth rate according to Globocan and industry data. Several early-stage licensing deals in this therapeutic area have exceeded $1 billion USD in recent years, highlighting the clinical value and commercial interest in this category.
Platform Validation and Future Outlook
The clinical advancement of PEP08 (搜索) and the ongoing second project serve as validation of XtalPi (搜索)'s AI and robotics discovery engine. The platform has demonstrated its ability to meet rigorous benchmarks in complex target spaces through a reproducible innovation model that translates biological insights into clinical assets.
"The clinical progress of PEP08 (搜索) and the ongoing collaboration of the second project are testaments to the synergy between our teams, and highlights the reliability of XtalPi (搜索)'s R&D platform in tackling complex targets," said Dr. Shuhao Wen, Chairman of XtalPi. "We look forward to further applying this model to deliver high-quality pipeline assets for our partners and generate sustained value for our shareholders."
Dr. Hong-Ren Wang, CEO and President of PharmaEngine (搜索), emphasized the strategic value of the collaboration: "PharmaEngine has been advancing its R&D capabilities, and our collaboration with XtalPi (搜索) exemplifies our ability to harness innovative technologies to propel next-generation discoveries in precision oncology. XtalPi's R&D platform played a key role in the early-stage discovery of PEP08 (搜索), providing a robust foundation for its clinical entry."
PharmaEngine (搜索) currently has one commercial product, ONIVYDE, approved for treating adult patients with metastatic pancreatic adenocarcinoma (搜索), and is advancing both PEP07 (CHK1 (搜索) inhibitor) and PEP08 (搜索) through Phase I clinical trials as part of its expanding oncology pipeline.